Matches in SemOpenAlex for { <https://semopenalex.org/work/W2419514399> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2419514399 endingPage "154" @default.
- W2419514399 startingPage "154" @default.
- W2419514399 abstract "![Graphic][1] Background MAGE-A3 is a cancer-testis antigen expressed in various human cancers, including MM, but not in normal non-gonadal tissues. MAGE-A3 expression inhibits apoptosis in MM cells, and has been associated with a more aggressive clinical course, making it a rational target for immunotherapy. Pre-autoSCT myeloablative conditioning provides tumor antigen release and a lymphopenic environment that may be ideal for expansion of primed PBL and generation of anti-myeloma immune responses.Patients and methods Eligibility for this pilot study required symptomatic MM within 1 year of diagnosis; MAGE-A+ MM cells by immunohistochemistry (IHC); at least VGPR following induction therapy; and meeting institutional criteria for autoSCT. The immunotherapy consists of a recombinant protein containing full-length MAGE-A3 fused to part of H. influenzae Protein D antigen, mixed with the AS15 immunostimulant (containing MPL, QS21, and CpG7909). Six weeks prior to SCT, patients received their 1st injection (300 µg recMAGE-A3 intramuscularly), followed 3 weeks later by steady-state leukopheresis to collect primed PBL. They then underwent stem cell mobilization and a melphalan 200 mg/m2-conditioned autoSCT, followed by re-infusion of unmanipulated PBL on day +3 after SCT, and 7 post-SCT injections (days +10, 31, 52, 73, 94, 180, and 270). Lenalidomide maintenance was permitted. The primary objectives were safety and tolerability. The secondary objectives were cellular and humoral immune responses and clinical outcomes. Humoral immunity was assessed by ELISA using baculovirus-generated recombinant MAGE-A3 protein.Results Of 93 pre-screened patients, 30 (32%) were MAGE-A+ by IHC. Of these, 13 (43%) enrolled. Reasons for non-enrollment were: did not achieve VGPR (n=6), declined/received other therapy (n=7), other (n=4). For enrolled patients, median age was 56; ISS stages I/II/III were 58%/25%/17%; 45% had high-risk cytogenetics at diagnosis (n=11 tested). Responses at enrollment were 12 VGPR and 1 CR; most (83%) had received VRD-based induction. All patients had adequate PBL collections (median 1.4 x 108 CD3+ cells/kg, range 1.0-2.6), and all collected stem cells successfully (median 11.4 x 106 CD34+ cells/kg, range 8.3 – 37.2). Autologous PBL infusions were well-tolerated, with no engraftment-like syndromes. Time to neutrophil recovery (median 11 days) and SCT-related toxicities were typical. The immunotherapy schedule was feasible with only 1 missed dose to date. Potential immunotherapy-related AE's (all grade 1 or 2) include injection site pain/reaction (n=6), myalgia/flu-like symptoms (n=5), fever/chills (n=2), fatigue (n=1), and rash (n=1). Three SAE's were observed: 1 immunotherapy-related (grade 2 myalgia requiring a 24-hour hospitalization), and 2 unrelated (grade 3 diarrhea, grade 3 atrial fibrillation with pulmonary edema). There have been no autoimmune toxicities and no deaths on study. Four patients initiated lenalidomide maintenance with no unexpected toxicities. Regarding immune responses, 12 of 12 (100%) evaluable patients have developed high-titer (>104) IgG antibodies against MAGE-A3 (Fig.). Responses were seen in all but 2 patients by day +31 post-SCT, and in all patients by day +75, persisting at 1 year post-SCT in both patients reaching this timepoint so far. All patients also developed strong IgG responses against Protein D. Clinically, at 3 months post-SCT, 50% of patients had achieved CR (33% stringent CR). With a median follow-up of 10 months post-SCT (range 1-20), 92% are progression-free, with follow-up ongoing.Conclusions MAGE-A3 protein immunotherapy plus autologous PBL transfer is feasible, has an acceptable safety profile, and is strongly immunogenic, capable of overcoming the profound immune suppression typically seen in MM patients post-autoSCT. The presence of IgG-type anti-MAGE antibodies implies the generation of a CD4 T cell response to induce Ig class-switching, though formal assessment of T cell responses against MAGE-A3 and other antigens are needed to confirm this, and are ongoing. Importantly, the use of an “off-the-shelf” immunotherapy product and unmanipulated autologous PBL transfer allows the treatment to be given at any transplant center. Further study of this approach as a strategy to consolidate post-autoSCT responses and potentially eliminate minimal residual disease is warranted.![Figure][2] Disclosures: Cohen: Bristol Meyers Squibb: Honoraria, Research Funding; Celgene: Membership on an entity’s Board of Directors or advisory committees; Onyx: Honoraria; Millennium: Honoraria. Bertolini: Ludwig Institute for Cancer Research: Employment. Pan: Ludwig Institute for Cancer Research: Employment. Venhaus: Ludwig Institute for Cancer Research: Employment. Fellague-Chebra: GlaxoSmithKline Vaccines: Employment. Gruselle: GlaxoSmithKline Vaccines: Employment. [1]: /embed/inline-graphic-2.gif [2]: pending:yes" @default.
- W2419514399 created "2016-06-24" @default.
- W2419514399 creator A5002472230 @default.
- W2419514399 creator A5005125179 @default.
- W2419514399 creator A5006038485 @default.
- W2419514399 creator A5007088159 @default.
- W2419514399 creator A5008791345 @default.
- W2419514399 creator A5009105564 @default.
- W2419514399 creator A5022794977 @default.
- W2419514399 creator A5026740596 @default.
- W2419514399 creator A5037411557 @default.
- W2419514399 creator A5039390734 @default.
- W2419514399 creator A5062518692 @default.
- W2419514399 creator A5069151798 @default.
- W2419514399 creator A5070646568 @default.
- W2419514399 creator A5078046623 @default.
- W2419514399 date "2013-11-15" @default.
- W2419514399 modified "2023-09-27" @default.
- W2419514399 title "MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT)" @default.
- W2419514399 doi "https://doi.org/10.1182/blood.v122.21.154.154" @default.
- W2419514399 hasPublicationYear "2013" @default.
- W2419514399 type Work @default.
- W2419514399 sameAs 2419514399 @default.
- W2419514399 citedByCount "0" @default.
- W2419514399 crossrefType "journal-article" @default.
- W2419514399 hasAuthorship W2419514399A5002472230 @default.
- W2419514399 hasAuthorship W2419514399A5005125179 @default.
- W2419514399 hasAuthorship W2419514399A5006038485 @default.
- W2419514399 hasAuthorship W2419514399A5007088159 @default.
- W2419514399 hasAuthorship W2419514399A5008791345 @default.
- W2419514399 hasAuthorship W2419514399A5009105564 @default.
- W2419514399 hasAuthorship W2419514399A5022794977 @default.
- W2419514399 hasAuthorship W2419514399A5026740596 @default.
- W2419514399 hasAuthorship W2419514399A5037411557 @default.
- W2419514399 hasAuthorship W2419514399A5039390734 @default.
- W2419514399 hasAuthorship W2419514399A5062518692 @default.
- W2419514399 hasAuthorship W2419514399A5069151798 @default.
- W2419514399 hasAuthorship W2419514399A5070646568 @default.
- W2419514399 hasAuthorship W2419514399A5078046623 @default.
- W2419514399 hasConcept C126322002 @default.
- W2419514399 hasConcept C147483822 @default.
- W2419514399 hasConcept C203014093 @default.
- W2419514399 hasConcept C2777701055 @default.
- W2419514399 hasConcept C2780868878 @default.
- W2419514399 hasConcept C2911091166 @default.
- W2419514399 hasConcept C71924100 @default.
- W2419514399 hasConcept C8891405 @default.
- W2419514399 hasConceptScore W2419514399C126322002 @default.
- W2419514399 hasConceptScore W2419514399C147483822 @default.
- W2419514399 hasConceptScore W2419514399C203014093 @default.
- W2419514399 hasConceptScore W2419514399C2777701055 @default.
- W2419514399 hasConceptScore W2419514399C2780868878 @default.
- W2419514399 hasConceptScore W2419514399C2911091166 @default.
- W2419514399 hasConceptScore W2419514399C71924100 @default.
- W2419514399 hasConceptScore W2419514399C8891405 @default.
- W2419514399 hasIssue "21" @default.
- W2419514399 hasLocation W24195143991 @default.
- W2419514399 hasOpenAccess W2419514399 @default.
- W2419514399 hasPrimaryLocation W24195143991 @default.
- W2419514399 hasRelatedWork W2276027266 @default.
- W2419514399 hasRelatedWork W2312168204 @default.
- W2419514399 hasRelatedWork W2326731062 @default.
- W2419514399 hasRelatedWork W241288141 @default.
- W2419514399 hasRelatedWork W2559032651 @default.
- W2419514399 hasRelatedWork W2560480169 @default.
- W2419514399 hasRelatedWork W2564288279 @default.
- W2419514399 hasRelatedWork W2570303732 @default.
- W2419514399 hasRelatedWork W2584378905 @default.
- W2419514399 hasRelatedWork W2594338738 @default.
- W2419514399 hasRelatedWork W2595893034 @default.
- W2419514399 hasRelatedWork W2778897040 @default.
- W2419514399 hasRelatedWork W2898986861 @default.
- W2419514399 hasRelatedWork W2922192036 @default.
- W2419514399 hasRelatedWork W2969180335 @default.
- W2419514399 hasRelatedWork W2979508297 @default.
- W2419514399 hasRelatedWork W2980175078 @default.
- W2419514399 hasRelatedWork W2980363913 @default.
- W2419514399 hasRelatedWork W3180740791 @default.
- W2419514399 hasRelatedWork W996750591 @default.
- W2419514399 hasVolume "122" @default.
- W2419514399 isParatext "false" @default.
- W2419514399 isRetracted "false" @default.
- W2419514399 magId "2419514399" @default.
- W2419514399 workType "article" @default.
!["![Graphic][1] Background MAGE-A3 is a cancer-testis antigen expressed in various human cancers, including MM, but not in normal non-gonadal tissues. MAGE-A3 expression inhibits apoptosis in MM cells, and has been associated with a more aggressive clinical course, making it a rational target for immunotherapy. Pre-autoSCT myeloablative conditioning provides tumor antigen release and a lymphopenic environment that may be ideal for expansion of primed PBL and generation of anti-myeloma immune responses.Patients and methods Eligibility for this pilot study required symptomatic MM within 1 year of diagnosis; MAGE-A+ MM cells by immunohistochemistry (IHC); at least VGPR following induction therapy; and meeting institutional criteria for autoSCT. The immunotherapy consists of a recombinant protein containing full-length MAGE-A3 fused to part of H. influenzae Protein D antigen, mixed with the AS15 immunostimulant (containing MPL, QS21, and CpG7909). Six weeks prior to SCT, patients received their 1st injection (300 µg recMAGE-A3 intramuscularly), followed 3 weeks later by steady-state leukopheresis to collect primed PBL. They then underwent stem cell mobilization and a melphalan 200 mg/m2-conditioned autoSCT, followed by re-infusion of unmanipulated PBL on day +3 after SCT, and 7 post-SCT injections (days +10, 31, 52, 73, 94, 180, and 270). Lenalidomide maintenance was permitted. The primary objectives were safety and tolerability. The secondary objectives were cellular and humoral immune responses and clinical outcomes. Humoral immunity was assessed by ELISA using baculovirus-generated recombinant MAGE-A3 protein.Results Of 93 pre-screened patients, 30 (32%) were MAGE-A+ by IHC. Of these, 13 (43%) enrolled. Reasons for non-enrollment were: did not achieve VGPR (n=6), declined/received other therapy (n=7), other (n=4). For enrolled patients, median age was 56; ISS stages I/II/III were 58%/25%/17%; 45% had high-risk cytogenetics at diagnosis (n=11 tested). Responses at enrollment were 12 VGPR and 1 CR; most (83%) had received VRD-based induction. All patients had adequate PBL collections (median 1.4 x 108 CD3+ cells/kg, range 1.0-2.6), and all collected stem cells successfully (median 11.4 x 106 CD34+ cells/kg, range 8.3 – 37.2). Autologous PBL infusions were well-tolerated, with no engraftment-like syndromes. Time to neutrophil recovery (median 11 days) and SCT-related toxicities were typical. The immunotherapy schedule was feasible with only 1 missed dose to date. Potential immunotherapy-related AE's (all grade 1 or 2) include injection site pain/reaction (n=6), myalgia/flu-like symptoms (n=5), fever/chills (n=2), fatigue (n=1), and rash (n=1). Three SAE's were observed: 1 immunotherapy-related (grade 2 myalgia requiring a 24-hour hospitalization), and 2 unrelated (grade 3 diarrhea, grade 3 atrial fibrillation with pulmonary edema). There have been no autoimmune toxicities and no deaths on study. Four patients initiated lenalidomide maintenance with no unexpected toxicities. Regarding immune responses, 12 of 12 (100%) evaluable patients have developed high-titer (>104) IgG antibodies against MAGE-A3 (Fig.). Responses were seen in all but 2 patients by day +31 post-SCT, and in all patients by day +75, persisting at 1 year post-SCT in both patients reaching this timepoint so far. All patients also developed strong IgG responses against Protein D. Clinically, at 3 months post-SCT, 50% of patients had achieved CR (33% stringent CR). With a median follow-up of 10 months post-SCT (range 1-20), 92% are progression-free, with follow-up ongoing.Conclusions MAGE-A3 protein immunotherapy plus autologous PBL transfer is feasible, has an acceptable safety profile, and is strongly immunogenic, capable of overcoming the profound immune suppression typically seen in MM patients post-autoSCT. The presence of IgG-type anti-MAGE antibodies implies the generation of a CD4 T cell response to induce Ig class-switching, though formal assessment of T cell responses against MAGE-A3 and other antigens are needed to confirm this, and are ongoing. Importantly, the use of an “off-the-shelf” immunotherapy product and unmanipulated autologous PBL transfer allows the treatment to be given at any transplant center. Further study of this approach as a strategy to consolidate post-autoSCT responses and potentially eliminate minimal residual disease is warranted.![Figure][2] Disclosures: Cohen: Bristol Meyers Squibb: Honoraria, Research Funding; Celgene: Membership on an entity’s Board of Directors or advisory committees; Onyx: Honoraria; Millennium: Honoraria. Bertolini: Ludwig Institute for Cancer Research: Employment. Pan: Ludwig Institute for Cancer Research: Employment. Venhaus: Ludwig Institute for Cancer Research: Employment. Fellague-Chebra: GlaxoSmithKline Vaccines: Employment. Gruselle: GlaxoSmithKline Vaccines: Employment. [1]: /embed/inline-graphic-2.gif [2]: pending:yes"](?object=%22!%5BGraphic%5D%5B1%5D%20Background%20MAGE-A3%20is%20a%20cancer-testis%20antigen%20expressed%20in%20various%20human%20cancers%2C%20including%20MM%2C%20but%20not%20in%20normal%20non-gonadal%20tissues.%20MAGE-A3%20expression%20inhibits%20apoptosis%20in%20MM%20cells%2C%20and%20has%20been%20associated%20with%20a%20more%20aggressive%20clinical%20course%2C%20making%20it%20a%20rational%20target%20for%20immunotherapy.%20Pre-autoSCT%20myeloablative%20conditioning%20provides%20tumor%20antigen%20release%20and%20a%20lymphopenic%20environment%20that%20may%20be%20ideal%20for%20expansion%20of%20primed%20PBL%20and%20generation%20of%20anti-myeloma%20immune%20responses.Patients%20and%20methods%20Eligibility%20for%20this%20pilot%20study%20required%20symptomatic%20MM%20within%201%20year%20of%20diagnosis%3B%20MAGE-A%2B%20MM%20cells%20by%20immunohistochemistry%20(IHC)%3B%20at%20least%20VGPR%20following%20induction%20therapy%3B%20and%20meeting%20institutional%20criteria%20for%20autoSCT.%20The%20immunotherapy%20consists%20of%20a%20recombinant%20protein%20containing%20full-length%20MAGE-A3%20fused%20to%20part%20of%20H.%20influenzae%20Protein%20D%20antigen%2C%20mixed%20with%20the%20AS15%20immunostimulant%20(containing%20MPL%2C%20QS21%2C%20and%20CpG7909).%20Six%20weeks%20prior%20to%20SCT%2C%20patients%20received%20their%201st%20injection%20(300%20%C2%B5g%20recMAGE-A3%20intramuscularly)%2C%20followed%203%20weeks%20later%20by%20steady-state%20leukopheresis%20to%20collect%20primed%20PBL.%20They%20then%20underwent%20stem%20cell%20mobilization%20and%20a%20melphalan%20200%20mg%2Fm2-conditioned%20autoSCT%2C%20followed%20by%20re-infusion%20of%20unmanipulated%20PBL%20on%20day%20%2B3%20after%20SCT%2C%20and%207%20post-SCT%20injections%20(days%20%2B10%2C%2031%2C%2052%2C%2073%2C%2094%2C%20180%2C%20and%20270).%20Lenalidomide%20maintenance%20was%20permitted.%20The%20primary%20objectives%20were%20safety%20and%20tolerability.%20The%20secondary%20objectives%20were%20cellular%20and%20humoral%20immune%20responses%20and%20clinical%20outcomes.%20Humoral%20immunity%20was%20assessed%20by%20ELISA%20using%20baculovirus-generated%20recombinant%20MAGE-A3%20protein.Results%20Of%2093%20pre-screened%20patients%2C%2030%20(32%25)%20were%20MAGE-A%2B%20by%20IHC.%20Of%20these%2C%2013%20(43%25)%20enrolled.%20Reasons%20for%20non-enrollment%20were%3A%20did%20not%20achieve%20VGPR%20(n%3D6)%2C%20declined%2Freceived%20other%20therapy%20(n%3D7)%2C%20other%20(n%3D4).%20For%20enrolled%20patients%2C%20median%20age%20was%2056%3B%20ISS%20stages%20I%2FII%2FIII%20were%2058%25%2F25%25%2F17%25%3B%2045%25%20had%20high-risk%20cytogenetics%20at%20diagnosis%20(n%3D11%20tested).%20Responses%20at%20enrollment%20were%2012%20VGPR%20and%201%20CR%3B%20most%20(83%25)%20had%20received%20VRD-based%20induction.%20All%20patients%20had%20adequate%20PBL%20collections%20(median%201.4%20x%20108%20CD3%2B%20cells%2Fkg%2C%20range%201.0-2.6)%2C%20and%20all%20collected%20stem%20cells%20successfully%20(median%2011.4%20x%20106%20CD34%2B%20cells%2Fkg%2C%20range%208.3%20%E2%80%93%2037.2).%20Autologous%20PBL%20infusions%20were%20well-tolerated%2C%20with%20no%20engraftment-like%20syndromes.%20Time%20to%20neutrophil%20recovery%20(median%2011%20days)%20and%20SCT-related%20toxicities%20were%20typical.%20The%20immunotherapy%20schedule%20was%20feasible%20with%20only%201%20missed%20dose%20to%20date.%20Potential%20immunotherapy-related%20AE's%20(all%20grade%201%20or%202)%20include%20injection%20site%20pain%2Freaction%20(n%3D6)%2C%20myalgia%2Fflu-like%20symptoms%20(n%3D5)%2C%20fever%2Fchills%20(n%3D2)%2C%20fatigue%20(n%3D1)%2C%20and%20rash%20(n%3D1).%20Three%20SAE's%20were%20observed%3A%201%20immunotherapy-related%20(grade%202%20myalgia%20requiring%20a%2024-hour%20hospitalization)%2C%20and%202%20unrelated%20(grade%203%20diarrhea%2C%20grade%203%20atrial%20fibrillation%20with%20pulmonary%20edema).%20There%20have%20been%20no%20autoimmune%20toxicities%20and%20no%20deaths%20on%20study.%20Four%20patients%20initiated%20lenalidomide%20maintenance%20with%20no%20unexpected%20toxicities.%20Regarding%20immune%20responses%2C%2012%20of%2012%20(100%25)%20evaluable%20patients%20have%20developed%20high-titer%20(%3E104)%20IgG%20antibodies%20against%20MAGE-A3%20(Fig.).%20Responses%20were%20seen%20in%20all%20but%202%20patients%20by%20day%20%2B31%20post-SCT%2C%20and%20in%20all%20patients%20by%20day%20%2B75%2C%20persisting%20at%201%20year%20post-SCT%20in%20both%20patients%20reaching%20this%20timepoint%20so%20far.%20All%20patients%20also%20developed%20strong%20IgG%20responses%20against%20Protein%20D.%20Clinically%2C%20at%203%20months%20post-SCT%2C%2050%25%20of%20patients%20had%20achieved%20CR%20(33%25%20stringent%20CR).%20With%20a%20median%20follow-up%20of%2010%20months%20post-SCT%20(range%201-20)%2C%2092%25%20are%20progression-free%2C%20with%20follow-up%20ongoing.Conclusions%20MAGE-A3%20protein%20immunotherapy%20plus%20autologous%20PBL%20transfer%20is%20feasible%2C%20has%20an%20acceptable%20safety%20profile%2C%20and%20is%20strongly%20immunogenic%2C%20capable%20of%20overcoming%20the%20profound%20immune%20suppression%20typically%20seen%20in%20MM%20patients%20post-autoSCT.%20The%20presence%20of%20IgG-type%20anti-MAGE%20antibodies%20implies%20the%20generation%20of%20a%20CD4%20T%20cell%20response%20to%20induce%20Ig%20class-switching%2C%20though%20formal%20assessment%20of%20T%20cell%20responses%20against%20MAGE-A3%20and%20other%20antigens%20are%20needed%20to%20confirm%20this%2C%20and%20are%20ongoing.%20Importantly%2C%20the%20use%20of%20an%20%E2%80%9Coff-the-shelf%E2%80%9D%20immunotherapy%20product%20and%20unmanipulated%20autologous%20PBL%20transfer%20allows%20the%20treatment%20to%20be%20given%20at%20any%20transplant%20center.%20Further%20study%20of%20this%20approach%20as%20a%20strategy%20to%20consolidate%20post-autoSCT%20responses%20and%20potentially%20eliminate%20minimal%20residual%20disease%20is%20warranted.!%5BFigure%5D%5B2%5D%20Disclosures%3A%20Cohen%3A%20Bristol%20Meyers%20Squibb%3A%20Honoraria%2C%20Research%20Funding%3B%20Celgene%3A%20Membership%20on%20an%20entity%E2%80%99s%20Board%20of%20Directors%20or%20advisory%20committees%3B%20Onyx%3A%20Honoraria%3B%20Millennium%3A%20Honoraria.%20Bertolini%3A%20Ludwig%20Institute%20for%20Cancer%20Research%3A%20Employment.%20Pan%3A%20Ludwig%20Institute%20for%20Cancer%20Research%3A%20Employment.%20Venhaus%3A%20Ludwig%20Institute%20for%20Cancer%20Research%3A%20Employment.%20Fellague-Chebra%3A%20GlaxoSmithKline%20Vaccines%3A%20Employment.%20Gruselle%3A%20GlaxoSmithKline%20Vaccines%3A%20Employment.%20%5B1%5D%3A%20%2Fembed%2Finline-graphic-2.gif%20%5B2%5D%3A%20pending%3Ayes%22){kind=link}